China Dasheng Biotechnology Co - Notification that Quarterly Report will be submitted late (NT 10-Q)
15 Maggio 2008 - 6:48PM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
o
Form 10-K
o
Form 20-F
o
Form 11-K
x
Form
10-Q
o
Form N-SAR
For the
Period Ended: March 31, 2008
o
Transition Report on
Form 10-KSB
o
Transition Report on
Form 10-QSB
o
Transition Report on
Form 20-F
o
Transition Report on
Form N-SAR
o
Transition Report on
Form 11-K
For the
Transition Period Ended:
Nothing
in this Form shall be construed to imply that the Commission has verified any
information contained herein.
If the
notification relates to a portion of the filing checked above, identify the
Item(s) to which the notification relates:
PART I -
COMPANY INFORMATION
Full Name
of Company:
China Dasheng Biotechnology
Company
Former
Name, if Applicable:
___________
c/o
American Union Securities Company 100 Wall Street – 15
th
Floor, New York, NY 10004
Address
of Principal Executive Office (Street and Number):
PART II -
RULES 12b-25 (b) and (c)
If the
subject report could not be filed without reasonable effort or expense and the
Company seeks relief pursuant to Rule 12b-25(b), the following should be
completed. (Check box if appropriate)
o
(a) The reasons
described in reasonable detail in Part III of this form could not be eliminated
without unreasonable effort or expense;
x
(b) The subject annual report or
semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form
N-SAR, or portion thereof will be filed on or before the fifteenth calendar day
following the prescribed due date; or the subject quarterly report or transition
report on Form 10-Q, or portion thereof, will be filed on or before the fifth
calendar day following the prescribed due date; and
o
(c) The accountant's
statement or other exhibit required by Rule 12b-25(c) has been attached if
applicable)
PART III
- NARRATIVE
Due to
the registrant’s limited staff and changed operations the subject report could
not be completed in a timely fashion.
PART IV -
OTHER INFORMATION
(1) Name
and telephone number of person to contact in regard to this
notification: F
ranK J.
Hariton (914) 674-4373
(2) Have
all or other periodic report required under section 13 or 15(d) of the
Securities Exchange Act of 1934 or section 30 of the Investment Company act of
1940 during the preceding 12 months or for such shorter period that the Company
was required to file such report(s) been filed? If the answer is no, identify
report(s).
x
Yes
o
No
(3) Is it
anticipated that any significant change in results of operations from the
corresponding period for the last fiscal year will be reflected by the earnings
statements to be included in the subject report or portion thereof?
x
Yes
o
No
The
Company has acquired operations in China since the corresponding period in the
prior year and these acquisitions will substantially change the Company’s
results.
If so:
attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.
The
Company has caused this notification to be signed on its behalf by the
undersigned, thereunto duly authorized.
China
Dasheng Biotechnology Company
|
Dated:
May 15, 2008
|
By:
/s/ JinJun Qi
|
Grafico Azioni China Dasheng Biotechnol... (PK) (USOTC:CDBT)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni China Dasheng Biotechnol... (PK) (USOTC:CDBT)
Storico
Da Giu 2023 a Giu 2024
